SUBSCRIBE

Breaking News on Contract Research, Manufacturing & Clinical Trials

Read more breaking news

 

 
Loading...

Wockhardt targets CMO space for diversification

By Gareth Macdonald , 14-Jun-2012
Last updated on 14-Jun-2012 at 10:47 GMT2012-06-14T10:47:25Z

Wockhardt sees the ‘fractured CMO space’ as providing opportunities for growth, diversification and greater capacity utilisation.

Mumbai-based Wockhardt is known primarily as a maker of generics and active pharmaceutical ingredients (APIs) - indeed earlier this week it predicted that plans to launch 15 copycat drugs in the US this year will be its key growth driver.

However, while generics will remain its main focus Wockhardt has also been building in the contract manufacturing space in recent years under the leadership of managing director Murtaza Khorakiwala and chairman Habil Khorakiwala.

Outsourcing-pharma.com spoke with company associate Vice President, Business Development - Contract Services Tom Salus at Interphex earlier this year, who set these efforts in the context of Wockhardt’s wider strategy.

Like many other major pharmaceutical companies we have capacity available in our human capital – research and development – and our facilities and with that we look for a way to optimise the utilisation of that knowhow” Salus said, explaining that this capacity ranges from solid dosages forms to extended release drugs and injectables.

Fragmented space

But while improved capacity utilisation is clearly a driver for Wockhardt, the firm also believes its dual Pharma-CMO status gives it an advantage over ‘pure play’ contractors.

I think we all realise that the contract manufacturing space is a fragmented industry, what is unique in the value-added proposition that Wockhardt has is that we are not a pure play CMO… we can use the investments that have already been made in our company for [our customer projects]."

William Reed Business Media Holiday video

Happy Holidays 2014 from William Reed Business Media!

The holidays are fast upon us, so let’s put ‘business’ to one side and...

Consolidation prevalent in industry, says third largest CMO

Consolidation prevalent in industry, says third largest CMO

Brad Carlson

VP Marketing 7 Sales, Aenova

Catalent commits to ADCs by upping its stake in Redwood

Catalent commits to ADCs by upping its stake in Redwood

Aileen Ruff

Global Strategic Marketing Director, Biologics and Sterile Technologies at Catalent...

Kemwell Talks Expansion and Approvals in India and the US

Kemwell Talks Expansion and Approvals in India and the US

Christian Ahlmark

Director of Corporate Development , Kemwell Biopharma

AMRI Exec Discusses 'New Bar' in FDA Enforcement

Following the completion of remediation efforts to deal with an FDA warning letter, Chris...

Happy holidays from William Reed Business Media!

Happy holidays from William Reed Business Media!

The working year is almost done, time to pause from ‘the business’ and embrace...

Aesica says academic partnerships are key for CMOs

Aesica says academic partnerships are key for CMOs

Alan Raymond

Sales & Marketing Director, Aesica Pharmaceuticals

Wockhardt targets CMO space for diversification

Wockhardt targets CMO space for diversification

Tom Salus

Associate Vice President, Business Development - Contract Services, Wockhardt

A bitter pill to swallow: young people dislike tablets more than old

A bitter pill to swallow: young people dislike tablets more than old

Thomas Hein

Director, Sales & Business Development, Hermes

Kemwell CEO says environmental efforts are worth the cost

Kemwell CEO says environmental efforts are worth the cost

Kemwell CEO Agneta Bergvall says drugmakers' efforts to make pharmaceutical manufacturing green are worth...

Catalent launches softgel products at CPhI: one vegetarian, one anti-abuse

Catalent launches softgel products at CPhI: one vegetarian, one anti-abuse

Will Downie

Senior VP Global Vusiness Development & Marketing, Catalent

AlpVision's iPhone Tech Offers Authentication in War on Counterfeits

AlpVision's iPhone Tech Offers Authentication in War on Counterfeits

Quincy Mattingly

Regional Manager, AlpVision

Cobra Biologics talks recent fill finish acquisition and future growth plans

Cobra Biologics talks recent fill finish acquisition and future growth plans

Philip Ridley-smith

Business Development & Marketing Manager, Cobra Biologics

Catalent says sharing with industry will not dull competetive edge

Catalent says sharing with industry will not dull competetive edge

Kurt Nielsen and Cornell Stamoran

Various, Catalent

Bend Research hunting new partnerships to boost bioavailability offering

Bend Research hunting new partnerships to boost bioavailability offering

David Lyon and Karen Coppens

Various, Bend Research and Dow

Changes to EU clinical trial laws will mean fairer playing field, says Clinipace

Changes to EU clinical trial laws will mean fairer playing field, says Clinipace

Andrea Schiefer

VP of European clinical operations and executive director of pharmacovigilance,...

Key Industry Events

 

Access all events listing

Our events, Events from partners...